On 24 November 2021, A.S.A. Al Hinai will defend his PhD dissertation, entitled: ‘Molecular Characterization and Residual Disease Monitoring of Acute Myeloid Leukemia’.
- Promotor
- Co-promotor
- Date
- Wednesday 24 Nov 2021, 13:00 - 14:30
- Type
- PhD defence
- Space
- Professor Andries Querido room
- Building
- Education Center
- Location
- Erasmus MC
Acute myeloid leukemia (AML) is a heterogeneous group of disorders with variable treatment outcomes attributable to the intrinsic genetic complexity, present at initial diagnosis and/
or evolving through disease evolution. These genetic lesions have a profound impact on patients response to treatment and prognosis. The advent of next-generation sequencing
has tremendously increased our knowledge and understanding of AML pathogenesis, heterogeneity, and clinical outcome. In addition, it revealed genetic precursor lesions associated with age-related clonal hematopoiesis or clonal hematopoiesis of indeterminate potential (CHIP). These advancements in the field of genomics of cancers, in general, and AML in particular, has led to improvements in the WHO classification of AML in 2016 and updates of the ELN risk stratification of AML in 2017.
The public defence will take place online at the Prof. Andries Queridoroom, 3rd floor Education Center, Erasmus MC. The ceremony will begin exactly at 13.00 PM.
